【24h】

Prognostic factors of infiltrating bladder tumors

机译:浸润性膀胱肿瘤的预后因素

获取原文
获取原文并翻译 | 示例
       

摘要

In France, invasive bladder cancer is the most frequent urologic malignancy after prostate carcinoma. The standard treatment of bladder cancer is radical cystectomy. New therapeutic approaches such as chemoradiation combination for a conservative procedure, neoadjuvant or adjuvant chemotherapy are still in development. In this prospect, a rigorous selection of patients is needed. This selection is based on prognostic criteria which could be divided into four groups: 1) the volume of the tumour including the tumour infiltration depth, the nodal status, the presence or not of hydronephrosis and the residual tumour burden after transuretral resection; 2) the histologic aspects including histologic grading, the presence or not of an epidermoid metaplasia, of in situ carcinoma or of thrombi; 3) the expression of circulating tumour cell biological markers; 4) the biologic characteristics of the tumour such as ploidy, presence of cytogenetic abnormalities, expression of Ki67, expression of oncogenes or tumour suppressor genes, expression of telomerase, expression of tumour antigens or growth factor receptors. This paper reviews the prognostic value of these different parameters.
机译:在法国,浸润性膀胱癌是继前列腺癌之后最常见的泌尿系恶性肿瘤。膀胱癌的标准治疗方法是根治性膀胱切除术。新的治疗方法,如保守疗法的化学放疗,新辅助或辅助化疗等仍在开发中。在这种前景下,需要对患者进行严格选择。该选择基于预后标准,可分为四组:1)肿瘤体积,包括肿瘤浸润深度,淋巴结状态,是否存在肾积水和经尿道切除后残余肿瘤负荷; 2)组织学方面,包括组织学分级,表皮样化生,原位癌或血栓的存在与否; 3)循环肿瘤细胞生物学标志物的表达; 4)肿瘤的生物学特性,例如倍性,细胞遗传异常的存在,Ki67的表达,癌基因或肿瘤抑制基因的表达,端粒酶的表达,肿瘤抗原或生长因子受体的表达。本文回顾了这些不同参数的预后价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号